1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>Japan

Political Shifts Shake Up Japan Price Cut Debate

 
• By Lisa Takagi

A shifting political power balance in Japan is leading to renewed debate on the pace of regular drug reimbursement price cuts.

(Shutterstock)

Japan’s changing political power balance is shaking up debate around policies for reimbursement price cuts for prescription drugs under the national health insurance (NHI) system, although the likely outcome is still unclear.

Prime Minister Shigeru Ishiba’s Liberal Democratic Party (LDP) has dominated both the Upper and Lower houses of Japan’s parliament for decades, but lost its majority in the latter in a snap general election in October, reflecting public anger over recent funding scandals

While the LDP government has recently provided more budget to support the development and launch of innovative drugs in Japan, including a total of JPY44

More from Japan

Japan Looks To Build Domestic Capacity In New Modalities

 
• By Lisa Takagi

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

Japan Pushes Generic Industry Reforms Via New Govt Fund

 
• By Lisa Takagi

Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.

Japan Expands Priority R&D List For Regular Vaccinations

 
• By Lisa Takagi

Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.

More from Pricing Debate